Mr. Michal Efraty reports

NEUROTHERA LABS' QUANTUM PLATFORM DEMONSTRATES COMPLETE END-TO-END HYBRID QUANTUM CLASSICAL WORKFLOW FOR CLINICAL DATA ANALYTIC

Another technological milestone has been achieved by Neurothera Labs Inc.'s quantum platform for clinical data analytics.

The platform has demonstrated a complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data through a fully integrated analytical framework from secure data ingestion and preparation through quantum-enabled analytical processing to the generation of biologically and clinically interpretable insights.

The demonstrated workflow showcases the platform's ability to process real-world clinical data sets using an integrated analytical framework that combines data preparation, quantum-enabled analysis and biologically relevant interpretation. The workflow was executed within a quantum simulation environment designed to emulate quantum computational processes relevant to the platform's analytical architecture.

The platform's proprietary analytical framework is designed to enable quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses of clinical trial and biomedical data sets.

The completed end-to-end clinical data analysis demonstrates the platform's ability to process clinical-grade data sets throughout the full analytical life cycle, from secure ingestion and preparation, through quantum-based analytical processing, and back to domain-relevant interpretability, within a single, integrated computational framework.

This milestone confirms that the platform can support a complete hybrid quantum-classical analytical workflow designed to address complex, high-dimensional biomedical data sets while applying quantum-inspired and quantum-enabled methodologies to uncover non-obvious patterns, all while maintaining alignment with downstream scientific interpretation requirements.

Building on this milestone, the platform's development road map includes expanding the scale of supported data sets, further optimizing its quantum algorithms, and conducting performance studies designed to evaluate the potential contribution of quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications.

The platform is being advanced through CliniQuantum, a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which the company holds 54.01 per cent.

About Neurotera Labs Inc.

Neurothera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.